1. EXECUTIVE SUMMARY
1.1 DISEASE OVERVIEW
1.2 GLOBAL SCENARIO
1.3 COUNTRY OVERVIEW
1.4 HEALTHCARE SCENARIO IN COUNTRY
1.5 PATIENT JOURNEY
1.6 HEALTH INSURANCE COVERAGE IN COUNTRY
1.7 ACTIVE PHARMACEUTICAL INGREDIENT (API)
1.8 RECENT DEVELOPMENTS IN THE COUNTRY
2. MARKET SIZE AND FORECASTING
2.1 EPIDEMIOLOGY OF DISEASE
2.2 MARKET SIZE (WITH EXCEL & METHODOLOGY)
2.3 MARKET SEGMENTATION (CHECK ALL SEGMENTS IN SEGMENTATION SECTION)
3. MARKET DYNAMICS
3.1 MARKET DRIVERS
3.2 MARKET RESTRAINTS
4 PREMIUM INSIGHTS
4.1 VALUE CHAIN ANALYSIS
4.2 COMPANY COMPARATIVE ANALYSIS
5. REIMBURSEMENT SCENARIO
5.1 REIMBURSEMENT REGULATION
5.2 REIMBURSEMENT PROCESS FOR DIAGNOSIS
5.3 REIMBURSEMENT PROCESS FOR TREATMENT
6. METHODOLOGY AND SCOPE
7 JAPAN ADRENOLEUKODYSTROPHY (ALD) THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION
7.1 OVERVIEW
7.2 ORAL
7.3 IV
7.4 PARENTERAL
7.5 INTRATHECAL
7.6 INTRACEREBRAL
7.7 SUBCUTANEOUS
8 JAPAN ADRENOLEUKODYSTROPHY (ALD) THERAPEUTICS MARKET, BY TREATMENT
8.1 OVERVIEW
8.2 ADRENAL GLAND TREATMENT
8.3 GENE THERAPY ORIENTED
8.4 DIETARY SUPPLEMENTS
9 JAPAN ADRENOLEUKODYSTROPHY (ALD) THERAPEUTICS MARKET, BY DIAGNOSIS
9.1 OVERVIEW
9.2 MOLECULAR GENETIC TESTING
9.3 NEWBORN SCREENING
9.4 ACTH STIMULATION TEST
9.5 MAGNETIC RESONANCE IMAGING (MRI)
9.6 OTHERS
10 JAPAN ADRENOLEUKODYSTROPHY (ALD) THERAPEUTICS MARKET, BY PATIENT TYPE
10.1 OVERVIEW
10.2 PEDIATRICS
10.3 ADULT
10.4 OLD AGE
11 JAPAN ADRENOLEUKODYSTROPHY (ALD) THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
11.1 OVERVIEW
11.2 HOSPITALS
11.3 PHARMACIES
12 JAPAN ADRENOLEUKODYSTROPHY (ALD) THERAPEUTICS MARKET, BY TYPE
12.1 OVERVIEW
12.2 CHILDHOOD CEREBRAL ALD
12.3 ADRENOMYELONEUROPATHY (AMN)
12.4 ADDISON'S DISEASE
14 JAPAN ADRENOLEUKODYSTROPHY (ALD) THERAPEUTICS MARKET, COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: JAPAN
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 POXEL SA
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 SERVICE PORTFOLIO
16.1.4 RECENT DEVELOPMENT
16.2 BLUEBIRD BIO INC.
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 SERVICES PORTFOLIO
16.2.4 RECENT DEVELOPMENT
16.3 VIKING TECHNOLOGIES
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 PRODUCT PORTFOLIO
16.3.4 RECENT DEVELOPMENTS
16.4 MINORYX THERAPEUTICS SL.
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 SERVICE PORTFOLIO
16.4.4 RECENT DEVELOPMENT
16.5 APTEEUS SAS
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 SERVICE PORTFOLIO
16.5.4 RECENT DEVELOPMENT
16.6 ASHVATTHA THERAPEUTICS LLC
16.6.1 COMPANY SNAPSHOT
16.6.2 REVENUE ANALYSIS
16.6.3 SERVICE PORTFOLIO
16.6.4 RECENT DEVELOPMENTS
16.7 NEUROVIA COMPANY
16.7.1 COMPANY SNAPSHOT
16.7.2 SERVICE PORTFOLIO
16.7.3 RECENT DEVELOPMENTS
16.8 AUTOBAHN THERAPEUTICS INC.
16.8.1 COMPANY SNAPSHOT
16.8.2 REVENUE ANALYSIS
16.8.3 SERVICE PORTFOLIO
16.8.4 RECENT DEVELOPMENTS
16.9 ALDAGEN INC.
16.9.1 COMPANY SNAPSHOT
16.9.2 REVENUE ANALYSIS
16.9.3 SERVICE PORTFOLIO
16.9.4 RECENT DEVELOPMENT
16.10 CELULARITY INC.
16.10.1 COMPANY SNAPSHOT
16.10.2 REVENUE ANALYSIS
16.10.3 SERVICE PORTFOLIO
16.10.4 RECENT DEVELOPMENTS
16.11 IMSTEM BIOTECHNOLOGY INC.
16.11.1 COMPANY SNAPSHOT
16.11.2 REVENUE ANALYSIS
16.11.3 SERVICE PORTFOLIO
16.11.4 RECENT DEVELOPMENTS
16.12 MEDDAY SA
16.12.1 COMPANY SNAPSHOT
16.12.2 REVENUE ANALYSIS
16.12.3 SERVICE PORTFOLIO
16.12.4 RECENT DEVELOPMENT
16.13 ORPHERIS INC.
16.13.1 COMPANY SNAPSHOT
16.13.2 REVENUE ANALYSIS
16.13.3 SERVICE PORTFOLIO
16.13.4 RECENT DEVELOPMENT
著作権 ©2022 無断複写・転載を禁じます
